Telegraph

7x24 real-time news feed, auto refreshBeijing Time：

🔄 Auto refresh 🔔 Sound 💬 Notify

All A·Important B·Normal #AI医疗 ✕

B

[Boehringer Ingelheim and Owkin reached an AI drug research and development license agreement] September 2nd, the artificial intelligence company Owkin announced on September 2, local time, that it had signed a license agreement with the German pharmaceutical company Boehringer Ingelheim. The latter will be able to use Owkin’s AI research platform and patient data to accelerate the development of drugs for cancer and immune-related diseases. The parties did not disclose the financial terms of the agreement.

#AI #drug research and development #AI medical09-02 21:05